SCHEMBL24499178

SCHEMBL24499178

CC(C)Sc1ccccc1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.44
GABRB2 P47870 2/20 0.44
LMNA P02545 3/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
FAAH O00519 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
GABRB1 P18505 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2C P28335 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
HTR2B P41595 1/20 0.41
GABRA2 P47869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22924477 0.82 GABRA1 (0.41) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL30548758 0.82 MAP2K7 (0.41) LMNAL3MBTL1MAP2K7CDC25ACDC25B
SCHEMBL944019 0.80 GABRA1 (0.48) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL4808650 0.80 GABRA1 (0.48) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL30389926 0.80 GABRA1 (0.48) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL5594562 0.78 GABRA1 (0.46) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL21032249 0.77 GABRA1 (0.41) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL18897631 0.76 GABRA1 (0.44) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL5594557 0.76 GABRA1 (0.44) GABRA1GABRB2LMNAGABRG2GABRB3
SCHEMBL6950806 0.76 LMNA (0.41) GABRA1GABRB2LMNAGABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 US disclosed
US-20220177462-A1 SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, RIPK3 GABRA1 2875/4885GABRB2 3932/4885LMNA 1598/4885
US-20220177462-A1 SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 GABRA1 2703/4885GABRB2 3492/4885LMNA 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.